肿瘤标志物在肺癌诊断、预后预测中的临床价值
|
摘要
目的分析肿瘤标志物在肺癌诊断及预后预测中的临床应用价值。方法选取肺癌患者68例为观察者,同期参与体检且结果健康者72例为对照组,检测两组血清肿瘤标志物。结果观察组糖类抗原(CA) 125、CA153、癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA21-1)水平均明显高于对照组(P<0. 05),小细胞肺癌组CA125、CA153、CEA、NSE、CYFRA21-1阳性率显著高于对照组(P<0. 05);肺鳞癌与肺腺癌组CA125、CA153、CEA、CYFRA21-1阳性率显著高于对照组(P<0. 05),肺鳞癌组CA125、CYFRA21-1阳性率显著高于小细胞肺癌组(P<0. 05),肺腺癌组CA125、CA153、CEA阳性率显著高于小细胞肺癌组(P<0. 05),肺腺癌组CA125、CA153、CEA、CYFRA21-1阳性率与肺鳞癌组比较差异显著(P<0. 05)。统计3年死亡情况,死亡患者中肿瘤标志物阳性率明显高于存活患者(P<0. 05),死亡患者两项及以上肿瘤标志物阳性率明显多于存活患者(P<0. 05)。结论肿瘤标志物可为肺癌患者的诊断及预后预测提供重要信息。
Objective To analyze the clinical value of tumor markers in the diagnosis and prognosis of lung cancer patients.Methods 68 patients with lung cancer were selected as observers. 72 patients who participated in the physical examination and healthy results were selected as the control group. The serum tumor markers were detected and compared. Results The levels of CA125,CA153,CEA,NSE and CYFRA21-1 in the observation group were significantly higher than those in the control group( P<0. 05). The positive rates of tumor markers in lung cancer patients with different pathological types were different. The 3-year mortality was analyzed. The number of positive tumor markers in the dead patients was significantly higher than that in the surviving patients( P<0. 05).Conclusions Tumor markers could provide important information for the diagnosis and prognosis of lung cancer patients.
Objective To analyze the clinical value of tumor markers in the diagnosis and prognosis of lung cancer patients.Methods 68 patients with lung cancer were selected as observers. 72 patients who participated in the physical examination and healthy results were selected as the control group. The serum tumor markers were detected and compared. Results The levels of CA125,CA153,CEA,NSE and CYFRA21-1 in the observation group were significantly higher than those in the control group( P<0. 05). The positive rates of tumor markers in lung cancer patients with different pathological types were different. The 3-year mortality was analyzed. The number of positive tumor markers in the dead patients was significantly higher than that in the surviving patients( P<0. 05).Conclusions Tumor markers could provide important information for the diagnosis and prognosis of lung cancer patients.
引文
1赵威,李恩有,刘珊珊,等.肺癌诊断方法的比较与研究进展[J].现代生物医学进展,2016;16(9):1766-8.
2张海晨,王浩,宋云霄,等.多项肿瘤标志物联合检测模型在肺癌诊断中的应用价值[J].检验医学,2018;33(7):590-6.
3刘连红,罗建祥,徐月君,等.不同病理类型肺癌患者血清肿瘤标志物CYFRA21-1、NSE和CEA水平的比较[J].武汉大学学报:医学版,2015;36(4):533-5.
4王云盛,郑海澜,刘红宇,等.多排螺旋CT诊断周围型肺癌的临床价值分析[J].医学影像学杂志,2015;25(12):2269-71.
5李少雷,马媛媛,雄英,等.常用血清肿瘤标志物在可手术肺癌患者预后中的价值[J].肿瘤防治研究,2018;45(1):24-8.
6 Shintani T,Matsuo Y,Iizuka Y,et al.Prognostic significance of serum CEA for non-small cell lung cancer patients receiving stereotactic body radiotherapy[J].Anticancer Res,2017;37(9):5161.
7左江华,李宗良,任宏涛.血清CEA、CA125、CA199联合检测在肺癌诊断中的应用价值[J].标记免疫分析与临床,2016;23(6):668-71.
8朱琳,郭广宏.血清CEA、CYFRA21-1、NSE、SCC和ProGRP联合检测在肺癌诊断中的价值[J].标记免疫分析与临床,2016;23(11):1237-41.
9王秋波,施雪峰,李巍,等.CEA、CYFRA21-1和CA125联合检测对非小细胞肺癌患者预后水平的评估价值[J].实用癌症杂志,2016;31(10):1601-4.
10裴宁.临床肺癌诊断中肿瘤标志物CA153、CA125检验应用的价值分析[J].中华肿瘤防治杂志,2016;24(s1):118-9.
11钱希铭,王晓明,高亚英,等.小细胞肺癌患者化疗前后血清ProGRP、CEP350、NSE含量评估及其与疾病预后的关系[J].海南医学院学报,2016;22(16):1848-50.
12彭彦,王燕,李峻岭,等.血清NSE、ProGRP和LDH在小细胞肺癌诊断治疗中的作用[J].中国肺癌杂志,2016;19(9):590-4.
13陈旭蓉.血清CEA、CYFRA21-1水平与非小细胞肺癌病理类型及分期的相关性分析[J].国际检验医学杂志,2017;38(17):2488-9.
2张海晨,王浩,宋云霄,等.多项肿瘤标志物联合检测模型在肺癌诊断中的应用价值[J].检验医学,2018;33(7):590-6.
3刘连红,罗建祥,徐月君,等.不同病理类型肺癌患者血清肿瘤标志物CYFRA21-1、NSE和CEA水平的比较[J].武汉大学学报:医学版,2015;36(4):533-5.
4王云盛,郑海澜,刘红宇,等.多排螺旋CT诊断周围型肺癌的临床价值分析[J].医学影像学杂志,2015;25(12):2269-71.
5李少雷,马媛媛,雄英,等.常用血清肿瘤标志物在可手术肺癌患者预后中的价值[J].肿瘤防治研究,2018;45(1):24-8.
6 Shintani T,Matsuo Y,Iizuka Y,et al.Prognostic significance of serum CEA for non-small cell lung cancer patients receiving stereotactic body radiotherapy[J].Anticancer Res,2017;37(9):5161.
7左江华,李宗良,任宏涛.血清CEA、CA125、CA199联合检测在肺癌诊断中的应用价值[J].标记免疫分析与临床,2016;23(6):668-71.
8朱琳,郭广宏.血清CEA、CYFRA21-1、NSE、SCC和ProGRP联合检测在肺癌诊断中的价值[J].标记免疫分析与临床,2016;23(11):1237-41.
9王秋波,施雪峰,李巍,等.CEA、CYFRA21-1和CA125联合检测对非小细胞肺癌患者预后水平的评估价值[J].实用癌症杂志,2016;31(10):1601-4.
10裴宁.临床肺癌诊断中肿瘤标志物CA153、CA125检验应用的价值分析[J].中华肿瘤防治杂志,2016;24(s1):118-9.
11钱希铭,王晓明,高亚英,等.小细胞肺癌患者化疗前后血清ProGRP、CEP350、NSE含量评估及其与疾病预后的关系[J].海南医学院学报,2016;22(16):1848-50.
12彭彦,王燕,李峻岭,等.血清NSE、ProGRP和LDH在小细胞肺癌诊断治疗中的作用[J].中国肺癌杂志,2016;19(9):590-4.
13陈旭蓉.血清CEA、CYFRA21-1水平与非小细胞肺癌病理类型及分期的相关性分析[J].国际检验医学杂志,2017;38(17):2488-9.